Pharmidex provides integrated preclinical services designed to accelerate the translation of novel therapeutic candidates from discovery toward clinical development. Our capabilities span in vivo pharmacology, DMPK, toxicology and translational bioanalysis, enabling end-to-end support across multiple therapeutic modalities and disease areas.

Our in vivo pharmacology services include efficacy, PK/PD and tolerability studies in established rodent and large-animal models across CNS, oncology, respiratory, inflammatory and metabolic disease. We routinely design bespoke models to address complex mechanistic hypotheses and early clinical differentiation needs. Our DMPK and ADME offering covers in vitro and in vivo PK, permeability, metabolism, protein binding, tissue distribution and drug-drug interaction studies, providing data packages required for compound triage, optimisation and IND-enabling decisions. Our bioanalysis and toxicology groups support discovery and GLP-aligned studies, including TK, clinical sample analysis, qPCR/ELISA, immunogenicity, dose formulation, and exploratory safety assessments. We offer both standard and bespoke workflows, including advanced modalities such as biologics, peptides, siRNA, GalNAc conjugates and viral vectors.

Pharmidex differentiates through integration, scientific depth and regulatory alignment. Cross-functional teams collaborate from study design through data interpretation, reducing handovers and shortening decision timelines for SME and biopharma clients. We operate GLP-accredited facilities and provide flexible engagement models that range from standalone studies to full preclinical work packages. Our mission is to de-risk therapeutic innovation, particularly for early-stage companies, by bridging discovery science with regulatory expectations and enabling faster, more cost-effective advancement of transformative therapeutics to the clinic.